Chen Yahong, Huang Aiqiong, Ao Wen, Wang Zhengwu, Yuan Jinjin, Song Qing, Wei Dahai, Ye Hanhui
1Mengchao Hepatobiliary Hospital of Fujian Medical University, 312 Xihong Road, Fuzhou, 350025 Fujian Province People's Republic of China.
2Fuzhou Infectious Disease Hospital, Fujian Medical University, 312 Xihong Road, Fuzhou, 350025 Fujian Province People's Republic of China.
Clin Proteomics. 2018 Dec 21;15:40. doi: 10.1186/s12014-018-9219-8. eCollection 2018.
(TM) is an emerging pathogenic fungus that can cause a fatal systemic mycosis in patients infected with human immunodeficiency virus (HIV). Although global awareness regarding HIV/TM coinfection is increasing little is known about the mechanism that mediates the rapid progression to HIV/AIDS disease in coinfected individuals. The aim of this study was to analyze the serum proteome of HIV/TM coinfected patients and to identify the associated protein biomarkers for TM in patients with HIV/AIDS.
We systematically used multiplexed isobaric tandem mass tag labeling combined with liquid chromatography mass spectrometry (LC-MS/MS) to screen for differentially expressed proteins in the serum samples from HIV/TM-coinfected patients.
Of a total data set that included 1099 identified proteins, approximately 86% of the identified proteins were quantified. Among them, 123 proteins were at least 1.5-fold up-or downregulated in the serum between HIV/TM-coinfected and HIV-mono-infected patients. Furthermore, our results indicate that two selected proteins (IL1RL1 and THBS1) are potential biomarkers for distinguishing HIV/TM-coinfected patients.
This is the first report to provide a global proteomic profile of serum samples from HIV/TM-coinfected patients. Our data provide insights into the proteins that are involved as host response factors during infection. These data shed new light on the molecular mechanisms that are dysregulated and contribute to the pathogenesis of HIV/TM coinfection. IL1RL1 and THBS1 are promising diagnostic markers for HIV/TM-coinfected patients although further large-scale studies are needed. Thus, quantitative proteomic analysis revealed molecular differences between the HIV/TM-coinfected and HIV-mono-infected individuals, and might provide fundamental information for further detailed investigations.
(某种真菌,此处未明确写出英文原名的中文译名)是一种新兴的致病真菌,可在感染人类免疫缺陷病毒(HIV)的患者中引起致命的系统性真菌病。尽管全球对HIV/(该真菌)合并感染的认识在不断提高,但对于合并感染个体中导致快速进展至HIV/AIDS疾病的机制知之甚少。本研究的目的是分析HIV/(该真菌)合并感染患者的血清蛋白质组,并鉴定HIV/AIDS患者中与(该真菌)相关的蛋白质生物标志物。
我们系统地使用多重等压串联质量标签标记结合液相色谱质谱联用(LC-MS/MS)技术,筛选HIV/(该真菌)合并感染患者血清样本中差异表达的蛋白质。
在总共鉴定出1099种蛋白质的数据集中,约86%的鉴定蛋白质得到了定量。其中,123种蛋白质在HIV/(该真菌)合并感染患者和HIV单感染患者的血清中至少上调或下调了1.5倍。此外,我们的结果表明,两种选定的蛋白质(IL1RL1和THBS1)是区分HIV/(该真菌)合并感染患者的潜在生物标志物。
这是第一份提供HIV/(该真菌)合并感染患者血清样本全球蛋白质组概况的报告。我们的数据揭示了作为感染期间宿主反应因子的相关蛋白质。这些数据为失调并导致HIV/(该真菌)合并感染发病机制的分子机制提供了新的线索。尽管需要进一步的大规模研究,但IL1RL1和THBS1是HIV/(该真菌)合并感染患者有前景的诊断标志物。因此,定量蛋白质组分析揭示了HIV/(该真菌)合并感染个体和HIV单感染个体之间的分子差异,并可能为进一步的详细研究提供基础信息。